Recurrent Cervical Carcinoma
43
3
7
24
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
14 trials with published results (33%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.3%
4 terminated out of 43 trials
85.7%
-0.8% vs benchmark
5%
2 trials in Phase 3/4
58%
14 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 24 completed trials
Clinical Trials (43)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
Donafenib for Recurrent Cervical Cancer